Single Oral Dose Comparative Bioavailability Study of Investigational Product in Healthy Human Subjects Under Fasting Conditions.

This study is an open-label, randomized, balanced, single oral dose, four-treatment, four-sequence, four-period, four-way cross-over comparative bioavailability trial designed to assess the bioavailability of different curcumin formulations in healthy adult volunteers under fasting conditions. A total of 24 subjects will be enrolled, each receiving four investigational products in a randomized sequence: non-formulated curcumin (90 mg, 1 capsule), Curcumin Dispersome formulation (600 mg; 2 x 300 mg capsules, each containing 90 mg curcumin), Turmipure Gold™ (300 mg, 1 capsule), and Qunol, Turmeric, Curcumin Complex, Extra Strength (1000 mg; 2 x 500 mg capsules). Each product will be administered as a single oral dose with 240 mL of water after at least 10 hours of fasting. Subjects will be housed in the clinical facility for at least 36 hours prior to dosing and remain for at least 24 hours post-dose during each period, with a minimum 7-day washout between periods. Safety will be monitored through clinical examination, vital signs, ECG, and laboratory assessments throughout the study. Blood samples for pharmacokinetic analysis will be collected at 13 time points in each period, and subjects will receive standardized turmeric-free meals and adhere to strict dietary and medication restrictions. The primary objective is to compare the bioavailability of the investigational products, with secondary objectives including the evaluation of safety and tolerability in the study population.